吉利德三代治疗基因4型代偿期丙型肝炎肝硬化复发1例报告

康艳艳; 何婷婷; 白云峰; 张宁; 刘冰; 宫嫚

doi:10.3969/j.issn.1001-5256.2017.11.027

吉利德三代治疗基因4型代偿期丙型肝炎肝硬化复发1例报告

DOI: 10.3969/j.issn.1001-5256.2017.11.027

1. 河北中医肝病医院
2. 解放军第三○二医院中西医结合诊疗与研究中心

基金项目:

解放军第三○二医院院长创新基金课题(QNPY2015002)；

详细信息

中图分类号: R512.63;R575.2
计量
- 文章访问数: 1884
- HTML全文浏览量: 12
- PDF下载量: 440
- 被引次数: 0
出版历程
- 出版日期: 2017-11-20

Recurrence after Epclusa treatment for compensated genotype 4 hepatitis C cirrhosis:a case report

Hebei TCM Liver Disease Hospital

Research funding:

摘要

摘要: <正>HCV共有6个基因型及不同亚型[1]。基因4型约占全球HCV感染者的20%[2],主要分布在中东及撒哈拉以南非洲地区。在埃及HCV感染者中,基因4型约占90%[3]。我国较常见的是1b和2a基因型,其中以1b型为主（56.8%）,其次为2型（24.1%）和3型（9.1%）,未见基因4型和5型报告,6型相对较少（6.3%）[4-6]。笔者收治基因4型丙型肝炎肝硬化代偿期患者1例,经美国吉利德三代（sofosbuvir+velpatasvir）规范抗病毒方案治疗24周后复发,现报告如下。
- 肝炎,丙型,慢性 /
- 肝硬化 /
- 复发 /
- 抗病毒药 /
- 病例报告
- hepatitis C, chronic /
- liver cirrhosis /
- recurrence /
- antiviral agents /
- case reports

HTML全文

参考文献(12)

[1]HANAFIAH KM, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.

[2]WANTUCK JM, AHMED A, NGUYEN MH.Review article:the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6[J].Aliment Pharmacol Ther, 2014, 39 (2) :137-147.

[3]KAMAL SM, NASSER IA.Hepatitis C genotype 4:what we know and what we don't yet know[J].Hepatology, 2008, 47 (4) :1371-1383.

[4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[5]KANG HY, CHEN CY, YANG J, et al.Efficiency analysis of medical ozone with PEG-IFN in the treatment of chronic hepatitis Cpatients curative[J].Int J Virol, 2016, 23 (3) :184-187. (in Chinese) 康海燕, 陈翠英, 杨静, 等.医用臭氧联合聚乙二醇干扰素治疗慢性丙型肝炎疗效分析[J].国际病毒学杂志, 2016, 23 (3) :184-187.

[6]LI JT, WEI HL, XI Q, et al.Relationship between TCM syndromes and amino acid mutation in NS5A aa, IL28B SNP of chronic HCV1b infection[J].J Changchun Univ Chin Med, 2015, 31 (4) :762-765. (in Chinese) 李京涛, 魏海梁, 席奇, 等.慢性丙型肝炎中医证型与HCV 1b亚型NS5A aa变异、IL28B SNP的关系[J].长春中医药大学学报, 2015, 31 (4) :762-765.

[7]ZHANG N, LUO SQ.Recommendations for WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection:a 2016 update[J].J Clin Hepatol, 2016, 32 (7) :1248-1249. (in Chinese) 张宁, 罗生强.《世界卫生组织指南:慢性丙型肝炎感染者的筛查、护理和治疗 (2016年更新版) 》推荐意见[J].临床肝胆病杂志, 2016, 32 (7) :1248-1249.

[8]FEENEY ER, CHUNG RT.Antiviral treatment of hepatitis C[J].BMJ, 2014, 349:g3308.

[9]GONZALEZ SA, KEEFFE EB.Management of chronic hepatitis C treament failures:role of consensus interferon[J].Biologics, 2009, 3:141-150.

[10]GURUSAMY KS, WILSON E, KORETZ RL, et al.Is sustailnedvirological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention[J].PLo S One, 2013, 8 (12) :e83313.

[11]HAYES N, CHAYAMA K.Emerding treatments for chronichepatitis C[J].J Formos Med Assoc, 2015, 114 (3) :204-215.

[12]LI MH, ZHANG YL, ZHANG L, et al.Study on effect of intensive treatment for refractory chronic hepatitis C patients[J].Chin J Exp Clin Virol, 2012, 26 (5) :374-378. (in Chinese) 李明慧, 张艳丽, 张璐, 等.难治性慢性丙型肝炎强化治疗疗效研究[J].中华实验和临床病毒学杂志, 2012, 26 (5) :374-378.

施引文献

资源附件(0)

访问统计